Serrated polyps have long been thought to lack malignant potential in the human colorectum. However, identification of the serrated pathway to colorectal cancer based on molecular biology has improved our understanding of the pathogenesis of colorectal cancers. Accordingly, serrated polyps such as traditional serrated adenoma and sessile serrated adenoma/polyps (SSA/P) are now considered to be precursor lesions of the serrated pathway. Recently, serrated polyps were classified into three subtypes, consisting of hyperplastic polyp, SSA/P, and traditional serrated adenoma, according to the World Health Organization classification. It has been suggested that SSA/P in the proximal colon are a precursor lesion of pathogenesis of colorectal cancer and are characterized by BRAF mutation and a CpG island methylator phenotype with or without microsatellite instability. However, SSA/P is more challenging to detect by colonoscopy and is likely to account for some interval cancers, particularly in the proximal colon because it presents flat or sessile, isochroous appearance, and occasionally has a mucous cap. Furthermore, the possibility has been raised that pathologists misclassify SSA/P as hyperplastic polyp. It is important for gastroenterologists to recognize the endoscopic features of serrated polyps to facilitate their detection and removal and also to establish postpolypectomy surveillance guidelines. In this review, we discuss the recent classification of serrated polyps; the molecular characteristics of the serrated pathway; appropriate diagnostic methods using endoscopy, including a new imageenhanced endoscopic technique; and management of these lesions.
Introduction
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. 1 Although adenoma is a well-recognized precursor lesion in colorectal carcinogenesis (adenoma-carcinoma sequence), it is not the only type of precursor lesion. Recently, it has been reported that serrated polyps are precursors of approximately 30% of CRCs. 2, 3 In the past, serrated polyps were mainly classified as hyperplastic polyp (HP) and were considered to have no malignant potential. 4 However, in an effort to understand the molecular biology of serrated polyps, these polyps are now considered to be heterogeneous groups characterized by a saw-toothed appearance of the colonic crypts. 5 Recently, serrated polyps have been pathologically classified as HP, sessile serrated adenoma/polyps (SSA/P), and traditional serrated adenoma (TSA) according to World Health Organization (WHO) classification. 6 Of these, SSA/P and TSA appear to be associated with a high risk for development of CRC. SSA/P in the proximal colon develop into CRC through a pathway characterized by BRAF mutation and a CpG island methylator phenotype (CIMP) with or without microsatellite instability (MSI). 7 However, SSA/P are difficult to detect owing to their flat morphology and isochronicity compared with protruding and reddish polyps such as TSA and conventional adenoma and thus are sometimes overlooking during colonoscopy. 8 Moreover, pathologists may misclassify SSA/P as HP because histological criteria for SSA/P have only recently been described. 9 Accordingly, endoscopists should be aware of the characteristics of SSA/P and also need to consider optimized detection, removal, and appropriate surveillance of SSA/P. In this review, we discuss the recent classification of serrated polyps, the molecular characteristics of the serrated pathway to CRC and the diagnosis including a new image-enhanced endoscopy and appropriate management of these polyps.
Classification of serrated polyps
In the last 30 years, our understanding of serrated polyps has dramatically changed because of various reasons, including improvements in colonoscopy techniques and equipment allowing for easier access to the proximal colon and better understanding of the molecular biology of the serrated pathway. Originally, serrated polyps were referred to as HP and were thought to be nonmalignant lesions, in contrast with conventional adenoma. 4 In the 1990s, Longacre and Fenoglio-Presier proposed the term "serrated adenoma", which are characterized by adenomatous polyp with crypt serration but not by the cytological features of HP, now known as TSA. 10 In 1996, Torlakovic and Snover coined the term "SSA", also known as SSA/P, which are characterized by a proximal location, large size, histologically prominent architectural distortion, and atypical nuclei in patients with serrated polyposis syndrome (SPS). 11 In 2005, the terms SSA and TSA were formally defined as separate entities by Snover and colleagues. 12 Currently, serrated polyps are defined as having a "saw-tooth" appearance of the colonic crypt epithelium. 6 They are classified into three major subtypes-HP, SSA/P, and TSAaccording to the latest WHO classification, although there is continued debate regarding the diagnostic criteria for and malignant potential of these polyps. We reported that aberrant crypt foci (ACF) in the proximal colon may be precursor lesions of SSA/P and that their pathological features include serrated architecture of the glands. 13 The serrated polyp subtype discussed in the succeeding section is shown in Table 1 .
Hyperplastic polyps
Hyperplastic polyps are characterized by the presence of straight crypts without significant distortion and are typically small (< 5 mm), located in the distal colon in 70% of cases.
14 HPs are the most common type of serrated polyps and have been suggested to account for approximately 80% to 95% of all serrated polyps and 29% to 40% of all polyps. 15, 16 Currently, HP are subclassified histologically as microvesicular hyperplastic polyps (MVHP), goblet cell-rich hyperplastic polyps (GCHP), and mucin-poor hyperplastic polyps (MPHP) according to WHO classification. 6 MVHP are characterized by the presence of small mucin droplets within the cytoplasm and serration pattern that is more prominent in the upper portion of the crypts. 17 MVHP occur predominantly in the distal colon (74%), although 26% occur in the proximal colon. 16 Of note, MVHP in the proximal colon are often positive for BRAF mutation (70%) and are also histologically similar to SSA/P. 16 Based on these data, MVHP are now considered to be a precursor lesion of SSA/P. 18 In contrast, GCHP have abundant goblet cells and show less serration. GCHP occur predominantly in the distal colon (> 90%), are typically very small (< 5 mm), and are frequently positive for KRAS mutations (50%). 4 However, its potential for malignancy remains unclear. MPHP characterized by a lack of cytoplasmic mucus represent a very rare type, and little is currently known about this form. 19 Although we have described the pathological features of these HPs, their clinical importance is still unknown.
Sessile serrated adenoma/polyps SSA/P are less common than HP and have been suggested to account for approximately 15% to 25% of all serrated polyps and 1.7% to 9% of all polyps. 8, 16, 20 SSA/P occur mostly in the proximal colon (75%) and are typically larger than HP (50% > 5 mm, 15-20% > 10 mm). Genetically, SSA/P are frequently positive for BRAF mutation. 6 Histologically, SSA/P are characterized by dilated crypts and crypts with horizontal growth of the bases in L-shapes or inverted T-shapes along the muscularis mucosae (Fig. 1 ). SSA/P often produce excessive extracellular mucin, including MUC5AC (gastric foveolar-type mucin) and MUC2 (normal colonic goblet cell mucin), which coats the surface of the polyp. 21 In addition, "pseudoinvasion", which is herniation of crypts through the muscularis mucosae, can also be seen, although it is not pathognomonic of SSA/P. 4 It has been suggested that SSA/P may originate from MVHP because of histological similarities and the common association with BRAF mutation. 22 However, some contradictory studies have reported that the main anatomical distribution of SSA/P (right-side colon) differs from that of MVHP (left-side colon) and also with respect to the presence of small SSA/P, 19 suggesting that some SSA/P may arise de novo. While, differentiation of SSA/P from MVHP is considered to be pathologically difficult. Recently, Gonzalo and associates identified annexin A10 as a candidate marker that can differentiate SSA/P from MVHP. 23 However, this has not yet been sufficiently validated in a large number of lesions, and therefore, further investigation is required. Recently, SSA/P have been subclassified as SSA/P without dysplasia, referred to as SSA/P and SSA/P with cytological dysplasia (SSCD). 6 It has been suggested that SSCD account for approximately 13.2% of SSA/P and 0.17% of all polyps, based on a large population-based study. 20 In addition, SSCD are thought to develop from SSA/P through hypermethylation of various genes (CIMP) including p16 and MLH1 24 resulting in early invasive cancer in the proximal colon. 19 This lesion may be more aggressive than conventional adenoma. 6 Accordingly, it is important to understand the endoscopic appearance and characteristics of SSCD as well as those of SSA/P.
Traditional serrated adenoma
Traditional serrated adenoma is the least frequent form of serrated polyps, accounting for approximately 1% of colorectal polyps, and predominantly occurs in the rectum and sigmoid colon. 16 Unlike HP and SSA/P, TSA presents usually pedunculated shapes. Histologically, TSA is characterized by villiform features and cells with elongated nuclei and an eosinophilic cytoplasm along with ectopic crypts. In addition, TSA is thought to be frequently associated with KRAS mutation and likely give rise to microsatellite stable (MSS) cancer through hypermethylation of the DNA repair gene MGMT (O6-methylguanine-DNA methyltransferase). 4 However, recent research has described that TSA have either KRAS (29-46%) or BRAF (27-55%) mutations, 25, 26 although mutations of these genes are mutually exclusive. Furthermore, Kim and coworkers demonstrated the presence of TSA components of MVHP and/or SSA/P in the proximal colon that frequently had BRAF mutation, 25 suggesting that development of TSA is heterogeneous and involves complicated molecular and morphological features. Although TSA has obvious malignant potential, the detailed mechanism of carcinogenesis remains to be elucidated.
Serrated polyposis syndrome
Serrated polyposis syndrome is characterized by multiple serrated polyps including HP, SSA/P, and TSA. The current clinical criteria for SPS according to the WHO include findings of: (1) at least five serrated polyps proximal to the sigmoid colon, two of which are greater than 10 mm in diameter, (2) any number of serrated polyps occurring proximal to the sigmoid colon in an individual who has a first-degree relative with serrated polyposis; or (3) more than 20 serrated polyps of any size distributed throughout the colon. 6 However, the prevalence of SPS is unknown, and no definitive gene mutation has yet been identified to correlate with the phenotype.
Of note, patients with SPS are considered to be at high risk for CRC. 27 Boparai and colleagues reported that in 35% (27/77) patients, CRC was detected of which 22 (28.5%) at initial endoscopy. CRC was detected during surveillance in 6.5% (5/77) patients. 28 In contrast, Carballal and associates recently reported that 15.8% (42/296) of patients in a multicenter study developed CRC with SPS during surveillance (cumulative CRC incidence 1.9% in 5 years), which was a lower rate than in previously published reports. Furthermore, they proposed that the presence of more than two SSA/P proximal to the splenic flexure and one or more proximal SSA/P with high-grade dysplasia were independent risk factors for CRC (incremental OR = 2, 95% CI = 1.22-3.24, p = 0.006) in SPS patients. Interestingly, they also noted that more than 50% of CRCs with SPS are located in the rectum and sigmoid colon. 29 These results raise the question as to whether the serrated pathway is a predominant contributor to the development of CRC with SPS, and therefore, further molecular-based investigation is required. In addition, SPS patients frequently have a family history of CRC. 30 One study reported an elevated relative risk (5.4) of CRC in first-degree relatives of patients with SPS. 31 Thus, it is recommended that colonoscopy should be performed at intervals of 1 year or less. 32 
Aberrant crypt foci and serrated polyps
Aberrant crypt foci were first described as lesions with large and thick crypts in methylene blue-stained colon specimens from mice treated with the colon carcinogen azoxymethane. 33 We previously observed human ACF in situ by methylene blue staining under magnifying colonoscopy. We found a significant correlation between the number of adenomas and number/size of rectal ACF in adenoma patients and that ACF were frequently positive for KRAS mutations. Moreover, we and other investigators showed that the number of ACF in the rectum of patients with colorectal adenoma and cancers is significantly higher than that of normal subjects. These data suggest that ACF in the distal colon are precursor lesions of adenoma and subsequent cancer. 34 In contrast, other studies have suggested that ACF in the distal colon may be precursor lesions of GCHP and TSA because of a similar anatomical distribution and common association with KRAS mutation. 35 However, there is a paucity of evidence to support this suggestion, and therefore, further investigation is needed. Recently, we examined the proximal colon in 36 patients with SSA/P and in normal subjects under magnifying colonoscopy. We found that the prevalence of ACF was significantly higher in SSA/P patients than in normal subjects and that there was a significant correlation between the numbers of SSA/P and ACF in SSA/P patients. Moreover, ACF in the proximal colon were frequently positive for BRAF mutations (66.7%), suggesting that ACF in the proximal colon may be one of precursor lesions of the SSA/P-cancer sequence in patients with SSA/P. 13 Rosenberg and colleagues hypothesized that serrated ACF are a precursor lesion of MVHP, which is thought to be precursor of SSA/P. 36 However, some contradictory studies have also been reported, 37 and further investigation is required.
Molecular features of the serrated pathway
It is well recognized that most CRCs develop through an adenoma-carcinoma sequence (also called chromosomal instability), where activation of KRAS mutation and loss of APC, P53, and chromosome 18 frequently occur. 2, 3, 38 Conversely, serrated polyps progress to cancer via the serrated pathway, characterized by the BRAF mutation, CIMP, with or without MSI, in the proximal colon.
2,38 ACF in the proximal colon (62-66.7%) 13, 36 and serrated polyps including MVHP (70%), 16 SSA/P (78-90%), 22 and to a lesser extent TSA (55%) 25 have hot-spot mutations in codon 15 of BRAF oncogene (V600E), which results in activation of the mitogen-activated protein kinase (MAPK) pathway and promotes cell proliferation and survival. Toyota and coworkers first described CIMP, in which hypermethylation of CpG islands causes loss of suppressor gene function, and CIMP is now thought to facilitate carcinogenesis in CRC. 39 Moreover, it has been reported that CIMP is strongly associated with BRAF mutation. 40 CIMP is determined by the analysis of hypermethylation of a panel of five genes such as MGMT, MLH1, p16, MINT1, MINT2, and MINT31 genes, although CIMP marker genes are not still standardized. Hypermethylation of at least two genes is thought to be CIMP-high and that of one genes is CIMP-low. 40 According to several studies of serrated polyps, the frequencies of CIMP range from 47% to 73% in MVHP and from 70% to 76% in SSA/P. 7, 8 However, in these studies, only a few genes representing CIMP panel markers were analyzed for methylation in serrated polyp tissue. We recently performed DNA methylation array analysis using the microarray-based integrated analysis of methylation by isochizomers (MIAMI) method in SSA/P. We identified six genes-PQLC1, HDHD3, RASL10B, FLI1, GJA3, and SLC26A2-that were commonly methylated in SSA/P, suggesting that these genes play an important role in SSA/P development. 13 DNA mismatch repair (MMR) gene (MLH1, MSH2, MSH6, and PMS2) silencing by methylation leading to high-frequency MSI (MSI-H) is considered to be the most important mechanism for progression of serrated polyps to cancers. 41 MSI was first reported in association with Lynch syndrome (hereditary nonpolyposis CRC), which is characterized by germline mutation in MMR genes (MLH1, MSH2, MSH6, and PMS2). 42 It was subsequently reported that some sporadic CRCs are associated with hypermethylation of MMR genes, in particular MLH1. 39 On the basis of MSI status, sporadic CRCs are classified into three subtypes. MSI-H tumors have MSI in at least two of five microsatellite markers, such as BAT25, BAT26, D2S123, D5S346, and D17S250, MSI-L tumors have MSI in only one marker, and MSS tumors do not have instability at any of the five markers. 43 This classification scheme is thought to be useful for predicting disease prognosis and for guiding decisions regarding treatment options such as checkpoint immunotherapy (i.e., anti-PD-1, PDL-1, and CTLA-4 antibody) in advanced CRC. 44, 45 Recent comprehensive genome-wide profiling of 276 CRC samples by the Cancer Genome Atlas (TCGA) Network has shown that 16% of CRC have multiple genetic and epigenetic mutations (e.g., ACVR2A, TGFBR2, BRAF, MSH3, and MSH6). In addition, in such mutated CRC, are referred to as "hypermutated CRC" or CRC with BRAF mutation, CIMP(+) and MSI-H originate from serrated polyps and are associated with a favorable prognosis. 46 In contrast, in a study by De Sousa and associates using an unsupervised classification strategy involving over 1100 individuals with CRC, it was reported that CRC with BRAF mutation, CIMP(+), and MSS can be associated with a poor prognosis, 47 suggesting that some serrated polyps develop to CRC with a poor prognosis. Thus, it is important to find and remove serrated polyps by endoscopic resection before they progress to cancer. Moreover, it has been reported that p53 mutation is associated with progession to cancer via the serrated pathway, although the p53 gene is commonly mutated or lost in the adenoma-carcinoma sequence. 3, 26 The p53 gene is the most frequently mutated gene (> 50%) in all human cancers, indicating that the gene plays a crucial role in preventing cancer development. 3 Fujita and colleagues observed p53 mutations in 41.7% of SSA/P with neoplastic progression 48 and, therefore, p53 may be one of the key genes involved in the progression to cancer via the serrated pathway. Taken together, these findings indicate that BRAF mutation may lead to small ACF and develop into MVHP through accumulation of methylated genes. Further methylation results in the development of SSA/P, and eventually, hypermethylation of MLH1 and/or p53 mutation may occur leading to the development of early invasive cancer (Fig. 2) . Notably, Fang and associates recently reported that the transcriptional repressor MAFG, which is upregulated by BRAF mutation, binds at the promoters of MLH1 and other CIMP genes. Furthermore, MAFG recruits BACH1, CHD8, and DNMT3Ba and result in hypermethylation of MLH1 and CIMP genes (Fig. 3) . 49 Therefore, MAFG and other genes may be useful for the identification of high-risk serrated polyps, which can rapidly progress to cancer. Conversely, it has been reported that MSS cancer with CIMP-low is strongly associated with KRAS mutations. A precursor lesion of these cancers may be GCHP, and to some extent TSA, as these polyps have KRAS mutation. 8 However, the molecular pathway by which this leads to the development of cancer is largely unclear. To further improve our understanding of the serrated pathway, valid preclinical animal model systems for this pathway must be developed. Some relevant preclinical animal models, such as a transgenic mouse model with mutated BRAF(V600E) expression, have been established. 50 Carragher and coworkers reported that induction of BRAF(V600E) in mice resulted in the formation of hyperplastic crypts in the small intestines. Furthermore, down-regulation of p16Ink4a through enhanced CpG methylation of exon 1 has been shown to lead to invasive tumors in the small intestines. 50 However, neither of these models completely recapitulates the serrated pathway of humans, 51 and therefore, they are not widely used. In vitro studies of the adenoma-carcinoma sequence using an intestinal epithelial organoid culture system have been published. 52 Such a system may demonstrate a novel molecular mechanism involving the serrated pathway, which could lead to improvement of diagnostic and therapeutic strategies for serrated polyps.
Endoscopic diagnosis
Serrated polyps are considered to be difficult to detect by fecal blood testing and computed tomographic colonography because they tend to be less prone to bleeding, are sessile, and flatter in morphology than conventional adenoma. 53 Thus, colonoscopy is now considered to be the best screening method for serrated polyps. However, the ability to detect these polyps by colonoscopy remains sufficient because of their indistinct margin and very flat morphology, which sometimes results in the polyps being overlooked. 53 Furthermore, differentiation of SSA/P from HP is also difficult because of their similar morphology. Accordingly, endoscopists must be aware of the endoscopic appearance of these polyps in order to improve their detection and facilitate removal of high-risk serrated polyps endoscopically in order to prevent CRC. HP are usually small (< 5 mm), flat or sessile, and pale, and they occur frequently in the rectum and sigmoid colon; 54 therefore, they may be less visible with insufflation during colonoscopy. However, HP do not receive much attention in the clinic because they are considered to have low potential for malignancy. SSA/P are also flat and sessile with indistinct edges, similar in color to the surrounding mucosa, and occur frequently in the proximal colon, 4,55 but are usually larger than HP (> 10 mm) (Fig. 4 ). Tadepalli and colleagues reported that the features of SSA/Ps include a mucus cap, a rim of debris or bubbles, alteration of the contour of a fold, and loss of the normal mucosa vascular pattern observable during routine colonoscopy. 56 However, the rate of detection of SSA/Ps by colonoscopy is very low (0-23%), 9, 57 suggesting that these endoscopic features make them inconspicuous compared with conventional adenoma and TSA. In addition, recent data indicate that colonoscopy may be less effective at preventing CRC in the proximal colon, 58 suggesting that achievement of a high SSA/P detection rate is required in order to prevent CRC. Importantly, Herzel and associates reported that the overall SSA/P detection rate improved from 0.2% in 2006 to 1.1% in 2008 as a result of improved interpretation of SSA/P, 9 suggesting that education and training of endoscopists and pathologists may be effective for improving the recognition and interpretation of SSA/P. It has been reported that chromoendoscopy and new image-enhanced endoscopy may also be useful for improving detection and/or differentiation of SSA/P. 16, [59] [60] [61] Hurlstone and colleagues reported that chromoendoscopy techniques detected more small and sessile lesions in the proximal colon compared with nonchromoendoscopy. 62 Furthermore, Kimura and coworkers reported that a novel type II-O (open) pit pattern (according to a modified version of the Kudo pit pattern classification system) has good sensitivity but low specificity for identifying SSA/P by magnifying chromoendoscopy. 59 However, this technique is considered to be highly operator-dependent and therefore is not widely used. Narrow-band imaging (NBI) is expected to improve the detection of SSA/P and differentiation of SSA/P from HP. 60 Hewell and colleagues reported that the NBI International Colorectal Endoscopic classification system has high accuracy in differentiating adenoma from HP. 63 However, this classification is considered to be insufficient for distinguishing SSA/P from HP. 64 In contrast, Yamashina and coworkers reported that magnifying NBI findings such as expanded crypt openings and thick and branched vessels are useful for distinguishing SSA/P from HP classified according to the International Colorectal Endoscopic system, 65 suggesting that magnifying NBI may serve to distinguish serrated polyps. Furthermore, Uraoka and colleagues reported that the combination of two significant predictive factors such as right-side location, lesion size of 10 mm or greater, and varicose microvascular vessels using conventional white light colonoscopy and/or NBI was associated with high accuracy in predicting the diagnosis of SSA/P without chromoendoscopy. 66 These findings suggest that, to differentiate SSA/P endoscopists need to pay attention not only to endoscopic feature but also location and size. Blue laser imaging (BLI), recently developed by Fujifilm (Tokyo, Japan), consists of two modes: BLI and BLI bright mode. 67 BLI bright mode, because of its brightness, was reported to improve flat polyp visibility for both experts and nonexperts, suggesting that this mode may also be useful for improving the detection of SSA/P (Fig. 5) . 61 Furthermore, it has been reported that autofluorescence imaging is useful for distinguishing SSCD from SSA/P alone. 68 However, this technique is highly operator-dependent and requires a high level of skills and knowledge. TSA are usually located in the distal colon and tend to be pedunculated or sessile, which makes endoscopic detection less difficult (Fig. 4) . 69 Figure 5 Endoscopic findings of conventional adenoma and SSA/P using image-enhanced endoscopy. Endoscopic findings of multiple conventional adenomas and SSA/P with mucus cap (white arrow) under white light (a). Conventional adenoma with microcapillary (MC) vessels using NBI with magnification (b). In contrast, there are no MC vessels in SSA/P using NBI with magnification (c). The presence of varicose microvascular vessels (VMV) are shown using NBI with magnification (white arrows). (d) Endoscopic findings of SSA/P with indistinct edges under white light (e). In contrast, visibility was improved by using BLI bright mode (f). [Colour figure can be viewed at wileyonlinelibrary.com]
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Endoscopic treatment
The Japanese Society of Gastroenterology has recently established evidence-based clinical guidelines for the management of colorectal polyps. 70 The guidelines recommended that SSA/P 10 mm or greater and TSA 5 mm or greater in size should be removed by endoscopic resection. Moreover, they also recommend that HP 10 mm or greater in the proximal colon be removed as they are difficult to discriminate from SSA/P, although follow-up alone is advised for HP 5 mm or less in size. Expert panel recommendations in the US advise that all serrated polyps should be removed with the exception of small HP in the rectum and sigmoid colon. 4, 32 Most SSA/P and TSA can be removed by endoscopic mucosal resection (EMR) or endoscopic piecemeal mucosal resection (EPMR), although optimal resection techniques are yet to be defined for serrated polyps. En bloc resection of SSA/P by EMR is considered to be difficult because of the indistinct margins and flat and/or sessile morphology of SSA/P; therefore, EPMR may be performed in clinical practice. 8, 26 However, EPMR has disadvantages such as poor pathological evaluation and local recurrence. Thus, after EPMR of SSA/P and TSA, patients have to undergo repeat colonoscopy in 3 to 6 months later to evaluate the polypectomy site for recurrence. 8, 71 The US Multisociety Task Force guidelines also recommend short interval for repeat colonoscopy (< 1 year) after EPMR. It has recently been reported that endoscopic submucosal dissection (ESD) is useful for en bloc resection of large sessile polyps. 72, 73 Several years ago, this technique was not widely used globally because the procedure takes a long time and is frequently associated with complications such as perforation. However, many hospitals have recently started to perform colorectal ESD as a result of improvements in ESD technique and equipment. 73 Thus, ESD may become a standard treatment technique for large serrated polyps in the near future.
Surveillance of serrated polyps
Several groups have published guidelines for colonoscopic surveillance of serrated polyps. 4, 32, 74 Most recently, the US Multisociety Task Force guidelines for surveillance after polypectomy recommended that SSA/P 10 mm larger, SSCD, and TSA can be surveyed at 3-year intervals. SSA/P smaller than 10 mm with no dysplasia can be surveyed at 5-year intervals. Small (< 10 mm) HP in rectosigmoid can be surveyed at 10-year intervals as these are very low-risk lesions. Serrated polyposis syndrome can be surveyed at 1-year intervals (Table 2) . 32 In Japan, surveillance guidelines for colon polyps, including adenoma and serrated polyps, have not yet been established. Therefore, Japanese Society of Gastroenterology recommends that follow-up colonoscopy should be performed within 3 years after polypectomy, in line with a retrospective study by the Japan Polyps Study Workgroup. 70, 75 However, the interval for high-risk serrated polyps such as SSA/P 10 mm or larger, SSCD, and TSA should be shorter because, if local recurrence occur as a result of incomplete endoscopic resection, these lesions may be interval cancer. Therefore, it is recommended that colonoscopic surveillance of these polyps be performed at 1-year intervals after initial polypectomy.
Conclusion
Serrated polyps develop to CRC through the serrated pathway and account for at least some interval cancers in the proximal colon. Therefore, endoscopists and pathologists need to understand the importance of serrated polyps as precursor lesions of CRCs. Endoscopists need to improve the detection rate of serrated polyps and to distinguish SSA/P from HP by applying advanced endoscopic imaging techniques to facilitate endoscopic removal. Likewise, pathologists should understand the histological features of serrated polyp subtypes to distinguish SSA/P from HP. Moreover, further investigations of the genetic and epigenetic features of serrated polyps will be needed. In the future, advances in molecular analysis (e.g., genome sequencing and micro RNA analysis) and establishment of preclinical animal models and organoid culture systems for serrated polyps are likely to improve the diagnosis and management of serrated polyps, leading to prevention of CRCs. 
